The mission of Dr. Doi's laboratory is to identify and investigate antimicrobial resistance of clinical concern among gram-negative bacterial pathogens. The areas of research include the genetic and molecular basis of emerging antimicrobial resistance mechanisms; the rapid diagnosis of resistance using phenotypic, genetic, and lipidomic approaches; and inhibitor-based drug discovery. Current efforts are focused on studying carbapenem-resistant Acinetobacter baumannii, a top-priority resistant pathogen, and fosfomycin resistance in Escherichia coli, the predominant cause of urinary tract infection in both healthcare and community settings. The latter work has expanded into drug discovery effort aimed at reversing resistance using an inhibitor-based approach.
- Bachelor of Medicine, Nagoya University School of Medicine, 1998
- MD, Nagoya University School of Medicine, 2004
- Medicine, Anjo Kosei Hospital, 1998
- Residency, Medicine, St. Luke's-Roosevelt Hospital Center, 2003
- Fellowship, Infectious Diseases, University of Pittsburgh Medical Center, 2005
Education & Training
Doi Y, Paterson DL, Egea P, Pascual A, López-Cerero L, Navarro MD, Adams-Haduch JM, Qureshi ZA, Sidjabat HE. Extended-spectrum and CMY-type beta-lactamase-producing Escherichia coli in clinical samples and retail meat from Pittsburgh, US, and Seville, Spain. Clin Microbiol Infect. 2009
Doi Y, Paterson DL, Adams-Haduch JM, Sidjabat HE, O'Keefe A, Endimiani A, Bonomo RA. Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 beta-lactamase. Antimicrob Agents Chemother. 2009; 53: 3159-61.
Sidjabat HE, Paterson DL, Qureshi ZA, Adams-Haduch JM, O'Keefe A, Pascual A, Rodríguez-Baño J, Doi Y. Clinical features and molecular epidemiology of CMY-type beta-lactamase-producing Escherichia coli. Clin Infect Dis. 2009; 48: 739-44.
Doi Y, Potoski BA, Adams-Haduch JM, Sidjabat HE, Pasculle AW, Paterson DL. Simple disk-based method for detection of KPC-type beta-lactamase using a boronic acid compound. J Clin Microbiol. 2008; 46: 4083-6.
Adams-Haduch JM, Paterson DL, Sidjabat HE, Pasculle AW, Potoski BA, Muto CA, Harrison LH, Doi Y. Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania. Antimicrob Agents Chemother. 2008; 52: 3837-43.
Shropshire W. C., Endres B. T., Borjan J., Aitken S. L., Bachman W. C., McElheny C. L., Khan A., Bhatti M. M., Saharasbhojane P., Kawai A., Shields R. K., Shelburne S. A., Doi Y. High-level ceftazidime-avibactam resistance in Escherichia coli conferred by the novel plasmid-mediated beta-lactamase CMY-185 variant. Journal of Antimicrobial Chemotherapy. 2023
Iovleva A., Mustapha M. M., Griffith M. P., Komarow L., Luterbach C., Evans D. R., Cober E., Richter S. S., Rydell K., Arias C. A., Jacob J. T., Salata R. A., Satlin M. J., Wong D., Bonomo R. A., van Duin D., Cooper V. S., Van Tyne D., Doi Y. Carbapenem-Resistant Acinetobacter baumannii in U.S. Hospitals: Diversification of Circulating Lineages and Antimicrobial Resistance. American Society for Microbiology. 2022; 13(2)
Munoz-Price L.S., Reeme A. E., Buchan B. W., Mettus R. T., Mustapha M. M., Van Tyne D., Shields R. K., Doi Y. Patient-to-Patient Transmission of Klebsiella pneumoniae Carbapenemase Variants with Reduced Ceftazidime-Avibactam Susceptibility. Antimicrobial Agents and Chemotherapy. 2019; 63(10)
- Antimicrobial Agents and Chemotherapy Editorial Board Member
- Journal of Clinical Microbiology
- Diagnostic Microbiology and Infectious Disease
- Honoree, University of Pittsburgh Honors Convocation, 2015
- Chair, Gram-Negative Committee, Antibacterial Resistance Leadership Group, 2015
- Program Committee Member, IDWeek, Infectious Diseases Society of America, 2018
